Clinical Trial Update: A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib [Phase 4]

View source ↗

Summary

This document describes a Phase 4 master protocol studying the long-term safety of Pirtobrutinib (LY3527727). The study is currently recruiting in chronic lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Status: RECRUITING